SpecificationsOrganism/cell line/tissueKH2 mouse ESC lineSexMaleSequencer or array typeIllumina HiSeq 2000Data formatRaw and analyzedExperimental factorsMek inhibition in WT KH2 ESCs;\
Mek inhibition in *Erk KO* ESCs;\
Erk knockout in *iErk1*; *Erk KO* ESCs.Experimental featuresComparison between WT KH2 ESCs treated with or without PD0325901 for 48 h (KH2_PD and KH2, respectively) shows the Mek inhibition effect in WT ESCs. Comparison between *iErk1*; *Erk KO* ESCs without Dox for 96 h, with or without PD0325901 treatment (P2_PD and P2, respectively) reveals the Mek inhibition effect in *Erk KO* ESCs.\
The *Erk* KO effect in ESCs is revealed by comparing *iErk1*; *Erk KO* ESCs with or without Dox for 48 h (P0 and P1, respectively).ConsentN/ASample source locationTianjin, China

1. Direct link to deposited data {#s0005}
================================

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70304>

2. Experimental design {#s0010}
======================

2.1. Cell lines {#s0015}
---------------

KH2 mouse embryonic stem cell (ESC) line is used as wild type cells [@bb0005]. *iErk1*; *Erk KO* cell lines are derived from KH2 ESCs as described previously [@bb0010]. Briefly, two endogenous *Erk1* alleles are disrupted by TALENs. Next, an exogenous *Erk1* gene is integrated into the engineered *ColA1* locus through FLPe recombinase-mediated recombination, resulting in a doxycycline (Dox)-inducible *Erk1* transgene (*iErk1*; *Erk1*^*−*/*−*^ ESCs). In the presence of Dox, both endogenous *Erk2* alleles in *iErk1*; *Erk1*^*−*/*−*^ cells are disrupted by Cas9. The resulting cell line is named *iErk1*; *Erk KO* ESCs*.* When cultured in medium supplemented with Dox, the exogenous *Erk1* transgene is expressed. Forty-eight hours after Dox withdrawal, no Erk protein can be detected. Thus, *iErk1*; *Erk KO* ESCs cultured in the absence of Dox for longer than 48 h are considered as *Erk KO* ESCs.

2.2. Samples prepared for RNA-sequencing {#s0020}
----------------------------------------

To gain insights into the role of Erk signaling in Mek inhibition of ESCs, six samples, WT KH2 ESCs treated with or without PD for 48 h (KH2_PD and KH2, respectively), iErk1; Erk KO ESCs cultured with Dox (P0), 48 and 96 h after Dox withdrawal (P1 and P2, respectively), and iErk1; Erk KO ESCs cultured without Dox for 96 h and treated with PD in the last 48 h (P2_PD), are subjected to RNA sequencing (RNA-seq) analysis.

Total RNA is extracted from cells using RNeasy Mini Kit (Qiagen). On-column DNase I digestion (DNase-Free DNase Set, Qiagen) is performed according to manufacturer protocols to eliminate genomic DNA contamination. Then the mRNA is enriched with the oligo(dT) magnetic beads (for eukaryotes), and is fragmented into short fragments (about 200 bp). With random hexamer-primer, the first strand of cDNA is synthesized, and then the second strand is synthesized. The double strand cDNA is purified with magnetic beads. The ends of the double strand cDNA are repaired, and a single nucleotide A (adenine) is added to the 3′-ends. Finally, sequencing adaptors are ligated to the fragments. The ligation products are amplified with PCR. For quality control, RNA and library preparation integrity are verified using Agilent 2100 BioAnalyzer system and ABI StepOnePlus Real-Time PCR System. Standard barcoded RNA-seq libraries are generated for sequencing with Illumina HiSeqTM 2000 (SE50). Construction of RNA sequencing library, sequencing with Illumina HiSeqTM 2000, and bioinformatic analysis are performed by BGI Tech (BGI, Shenzhen, China).

2.3. Data analysis {#s0025}
------------------

By base calling, the original image data produced by the sequencer is translated into sequences, which are defined as "raw reads"(or "raw data") and saved as ".fastq" files. Raw data is filtered to remove sequences of low quality, and only high quality reads are retained as the clean reads (clean data) and used for the subsequent analysis. The filtering procedure includes the following three steps: (a) remove reads with adaptor sequences. (b) Remove reads in which the percentage of unknown bases (N) is greater than 10%. (c) Remove low quality reads. If the percentage of the low quality base (base with quality value ≤ 5) is greater than 50% in a read, we define this read as low quality. Clean reads are mapped to reference sequences (mm9) using SOAPaligner/SOAP2 [@bb0015]. No more than 2 mismatches are allowed in the alignment. The sequencing and alignment results are summarized in [Table 1](#t0005){ref-type="table"}. Reads Per kilobase per Million reads (RPKM) is calculated to represent the gene expression level, and saved as ".Gene.rpkm.xls" files. The formula is RPKM = 10^6^ × C/(N × L/10^3^) [@bb0020]. Here RPKM(A) is the expression level of gene A, C is the number of reads that uniquely aligned to gene A, N is the total number of reads that uniquely aligned to all genes, and L is the number of bases of gene A. If there is more than one transcript for a gene, the longest one is used to calculate its expression level and coverage.

2.4. Analysis of differentially expressed genes {#s0030}
-----------------------------------------------

The RPKM values are used for comparing the difference of gene expression among samples. The criteria of more than two fold change and false discovery rate (FDR) \< 0.001 are used to identify lists of differentially expressed genes (DEGs) in each compared group. Three lists of DEGs, Meki (*WT*), Meki (*Erk KO*), and *Erk* KO, are generated by paired comparisons of KH2_PD and KH2, P2_PD and P2, and P1 and P0, respectively ([Fig. 1](#f0005){ref-type="fig"}A). Further comparison of these three lists of DEGs reveals that *Erk* KO are quite different from Meki (*WT*) ([Fig. 1](#f0005){ref-type="fig"}B), consistent with our observation that *Erk* KO and Mek inhibition have distinct effect on the self-renewal and proliferation of mouse ESCs [@bb0010]. Moreover, Meki (*Erk KO*) and Meki (*WT*) share a significant portion of genes ([Fig. 1](#f0005){ref-type="fig"}C), suggesting that these genes are regulated by Mek inhibition, regardless of the presence or absence of Erk.
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![RNA-seq data reveal an Erk-independent function of Mek. (A) Paired comparisons of KH2_PD and KH2, P2_PD and P2, and P1 and P0, generate three lists of DEGs, Meki (*WT*), Meki (*Erk KO*), and *Erk* KO. (B) The DEG lists of Meki (*WT*) and *Erk* KO are quite different. (C) There are significant overlaps between the DEG lists of Meki (*WT*) and Meki (*Erk KO*), suggesting Mek inhibition still regulates the overlapping genes even in the absence of Erk.](gr1){#f0005}

###### 

Summary of the sequencing and mapping result.

  Sample ID   Total reads            Total base pairs        Total mapped reads    Perfect match        ≤ 2 bp mismatch      Unique match         Multi-position match   Total unmapped reads
  ----------- ---------------------- ----------------------- --------------------- -------------------- -------------------- -------------------- ---------------------- ----------------------
  P0          11,451,219 (100.00%)   561,109,731 (100.00%)   9,917,796 (86.61%)    8,844,577 (77.24%)   1,073,219 (9.37%)    9,420,231 (82.26%)   497,565 (4.35%)        1,533,423 (13.39%)
  P1          11,817,535 (100.00%)   579,059,215 (100.00%)   10,238,164 (86.64%)   9,151,544 (77.44%)   1,086,620 (9.19%)    9,716,556 (82.22%)   521,608 (4.41%)        1,579,371 (13.36%)
  P2          12,089,054 (100.00%)   592,363,646 (100.00%)   10,535,239 (87.15%)   9,321,739 (77.11%)   1,213,500 (10.04%)   9,969,006 (82.46%)   566,233 (4.68%)        1,553,815 (12.85%)
  P2_PD       11,900,370 (100.00%)   583,118,130 (100.00%)   10,431,854 (87.66%)   9,250,291 (77.73%)   1,181,563 (9.93%)    9,845,925 (82.74%)   585,929 (4.92%)        1,468,516 (12.34%)
  KH2         11,962,550 (100.00%)   586,164,950 (100.00%)   9,761,489 (81.60%)    8,473,892 (70.84%)   1,287,597 (10.76%)   9,105,242 (76.11%)   656,247 (5.49%)        2,201,061 (18.40%)
  KH2_PD      11,997,433 (100.00%)   587,874,217 (100.00%)   9,709,863 (80.93%)    8,410,837 (70.11%)   1,299,026 (10.83%)   9,067,108 (75.58%)   642,755 (5.36%)        2,287,570 (19.07%)
